NCT02209688View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

March 31, 2000

Conditions
Healthy
Interventions
DRUG

ESR 1150 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY